RXRX RECURSION PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1601830 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $8.93M 36 sales by 5 insiders
- Filings on record
- 457 since 2021-07-06, latest 2026-09-16 17:52
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Borgeson Blake | Dir | — | $4.10M |
| Gibson Christopher | Dir | — | $3.84M |
| Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| Taylor Ben R | CFO | — | $157.7K |
| Bumpus Namandje | Dir | — | $28.1K |
| Michor Franziska | Dir | — | — |
| Hallett David | CSO | — | — |
| Dar Zavain | Dir | — | — |
| Li Dean Y | Dir | — | — |
| Sun Elaine D | Dir | — | — |
Transactions 743
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-07-08 | 2022-07-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.05 | -37.1K | 528.9K | -7% | -$336.1K |
| D | 2022-07-08 | 2022-07-07 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 547.4K | +3% | $0 |
| DMI | 2022-07-08 | 2022-07-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.07 | -2,500 | 0 | -100% | -$22.7K |
| DMI | 2022-07-08 | 2022-07-07 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| 2022-07-06 | 2022-07-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,409 | 619.0K | +0.2% | $0 | |
| 2022-07-06 | 2022-07-01 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +2,224 | 31.5K | +8% | $0 | |
| 2022-07-06 | 2022-07-01 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +1,186 | 7.67M | +0.0% | $0 | |
| 2022-07-06 | 2022-07-01 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +1,631 | 156.1K | +1% | $0 | |
| 2022-07-06 | 2022-07-01 | RXRX | Bogue Zachary | Dir, 10% | A - Grant | $0.00 | +1,260 | 4,012 | +46% | $0 | |
| D | 2022-06-16 | 2022-06-14 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +18.1K | 617.6K | +3% | $0 |
| D | 2022-06-16 | 2022-06-14 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +18.1K | 154.5K | +13% | $0 |
| D | 2022-06-16 | 2022-06-14 | RXRX | HERSHBERG ROBERT | Dir | A - Grant | $0.00 | +18.1K | 26.0K | +231% | $0 |
| D | 2022-06-16 | 2022-06-14 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +18.1K | 29.3K | +163% | $0 |
| D | 2022-06-16 | 2022-06-14 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +18.1K | 18.1K | New | $0 |
| D | 2022-06-16 | 2022-06-14 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +18.1K | 7.67M | +0.2% | $0 |
| DMI | 2022-06-06 | 2022-06-02 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2022-06-06 | 2022-06-02 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 537.5K | +6% | +$77.5K |
| DM | 2022-06-06 | 2022-06-02 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.09 | -39.7K | 516.3K | -7% | -$241.7K |
| D | 2022-06-06 | 2022-06-02 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 534.8K | +4% | $0 |
| DMI | 2022-06-06 | 2022-06-02 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.34 | -2,500 | 0 | -100% | -$15.9K |
| 2022-05-18 | 2022-05-16 | RXRX | Virani Shafique | Chief Corp. Dev. Off | F - Tax | $5.67 | -870 | 104.4K | -0.8% | -$4,933 | |
| 2022-05-18 | 2022-05-16 | RXRX | Secora Michael | CFO | F - Tax | $5.67 | -1,069 | 588.7K | -0.2% | -$6,061 | |
| 2022-05-18 | 2022-05-16 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $5.67 | -1,458 | 206.6K | -0.7% | -$8,267 | |
| 2022-05-18 | 2022-05-16 | RXRX | Doyle Ramona | Chief Medical Off | F - Tax | $5.67 | -832 | 121.1K | -0.7% | -$4,717 | |
| 2022-05-18 | 2022-05-16 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $5.67 | -5,764 | 506.2K | -1% | -$32.7K | |
| DMI | 2022-05-06 | 2022-05-04+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +5,000 | 1,000 | New | $0 |
| DMI | 2022-05-06 | 2022-05-04+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.46 | -5,000 | 0 | -100% | -$32.3K |
| DM | 2022-05-06 | 2022-05-04+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.47 | -50.3K | 512.0K | -9% | -$325.7K |
| DM | 2022-05-06 | 2022-05-04+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +37.0K | 530.5K | +7% | $0 |
| D | 2022-05-06 | 2022-05-04 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 525.3K | +6% | +$77.5K |
| DM | 2022-05-02 | 2022-04-28+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.14 | -75.7K | 494.1K | -13% | -$464.4K |
| DM | 2022-05-02 | 2022-04-28+ | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +88.0K | 488.7K | +22% | +$218.3K |
| DMI | 2022-05-02 | 2022-04-28+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.19 | -5,000 | 0 | -100% | -$30.9K |
| DMI | 2022-05-02 | 2022-04-28+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +5,000 | 1,000 | New | $0 |
| DM | 2022-05-02 | 2022-04-28+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +37.0K | 512.6K | +8% | $0 |
| DM | 2022-04-25 | 2022-04-21+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +49.0K | 438.6K | +13% | $0 |
| DM | 2022-04-25 | 2022-04-21+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.17 | -75.1K | 420.1K | -15% | -$463.7K |
| D | 2022-04-25 | 2022-04-25 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -12.0K | 444.7K | -3% | $0 |
| DMI | 2022-04-25 | 2022-04-21+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +5,000 | 500 | New | $0 |
| DMI | 2022-04-25 | 2022-04-21+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.09 | -5,000 | 0 | -100% | -$30.5K |
| DM | 2022-04-25 | 2022-04-21+ | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +88.0K | 438.8K | +25% | +$218.3K |
| D | 2022-04-20 | 2022-04-18 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 413.3K | +5% | $0 |
| DM | 2022-04-20 | 2022-04-18 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.84 | -35.8K | 394.8K | -8% | -$245.1K |
| DMI | 2022-04-20 | 2022-04-18 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DMI | 2022-04-20 | 2022-04-18 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.71 | -2,500 | 0 | -100% | -$16.8K |
| D | 2022-04-20 | 2022-04-18 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 412.1K | +12% | +$109.1K |
| DMI | 2022-04-18 | 2022-04-14 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.51 | -2,500 | 0 | -100% | -$18.8K |
| DM | 2022-04-18 | 2022-04-14 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.56 | -34.5K | 368.1K | -9% | -$261.0K |
| DMI | 2022-04-18 | 2022-04-14 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| D | 2022-04-18 | 2022-04-14 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 384.1K | +13% | +$109.1K |
| D | 2022-04-18 | 2022-04-14 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 386.6K | +5% | $0 |
| DMI | 2022-04-12 | 2022-04-08 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DMI | 2022-04-12 | 2022-04-08 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.71 | -2,500 | 0 | -100% | -$16.8K |
| DM | 2022-04-12 | 2022-04-08 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.59 | -36.9K | 340.1K | -10% | -$243.1K |
| D | 2022-04-12 | 2022-04-08 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 358.5K | +5% | $0 |
| D | 2022-04-12 | 2022-04-08 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 358.5K | +14% | +$109.1K |
| DMI | 2022-04-11 | 2022-04-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.51 | -2,500 | 0 | -100% | -$16.3K |
| DMI | 2022-04-11 | 2022-04-07 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| DM | 2022-04-11 | 2022-04-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.54 | -36.7K | 314.5K | -10% | -$240.3K |
| D | 2022-04-11 | 2022-04-07 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 332.8K | +15% | +$109.1K |
| D | 2022-04-11 | 2022-04-07 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 333.0K | +6% | $0 |
| DMI | 2022-04-08 | 2022-04-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2022-04-08 | 2022-04-06 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 306.1K | +17% | +$109.1K |
| DMI | 2022-04-08 | 2022-04-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.56 | -2,500 | 0 | -100% | -$16.4K |
| D | 2022-04-08 | 2022-04-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 307.2K | +6% | $0 |
| DM | 2022-04-08 | 2022-04-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.77 | -35.8K | 288.7K | -11% | -$242.6K |
| DMI | 2022-04-07 | 2022-04-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DM | 2022-04-07 | 2022-04-05 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.44 | -34.5K | 262.1K | -12% | -$256.3K |
| DMI | 2022-04-07 | 2022-04-05 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.31 | -2,500 | 0 | -100% | -$18.3K |
| D | 2022-04-07 | 2022-04-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 280.6K | +7% | $0 |
| D | 2022-04-07 | 2022-04-05 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 278.0K | +19% | +$109.1K |
| 2022-04-05 | 2022-04-01 | RXRX | Bogue Zachary | Dir, 10% | A - Grant | $0.00 | +1,382 | 2,752 | +101% | $0 | |
| 2022-04-05 | 2022-04-01 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +1,788 | 136.4K | +1% | $0 | |
| 2022-04-05 | 2022-04-01 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +2,438 | 11.1K | +28% | $0 | |
| 2022-04-05 | 2022-04-01 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +1,300 | 7.65M | +0.0% | $0 | |
| 2022-04-05 | 2022-04-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,544 | 599.5K | +0.3% | $0 | |
| D | 2022-04-04 | 2022-03-31 | RXRX | Doyle Ramona | Chief Medical Off | M - OptEx | $2.48 | +9,072 | 121.9K | +8% | +$22.5K |
| DM | 2022-03-15 | 2022-03-11+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +336.1K | 464.0K | +263% | $0 |
| DM | 2022-03-15 | 2022-03-11+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $6.48 | -336.1K | 234.0K | -59% | -$2.18M |
| D | 2022-03-09 | 2022-03-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.30 | -300.0K | 234.0K | -56% | -$2.19M |
| D | 2022-03-09 | 2022-03-07 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +300.0K | 534.0K | +128% | $0 |
| D | 2022-03-08 | 2022-03-04 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +58.5K | 208.0K | +39% | +$62.0K |
| D | 2022-03-01 | 2022-02-28 | RXRX | Doyle Ramona | Chief Medical Off | M - OptEx | $2.48 | +15.6K | 112.9K | +16% | +$38.8K |
| D | 2022-02-24 | 2022-02-22 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 334.0K | +43% | $0 |
| D | 2022-02-24 | 2022-02-22 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $10.22 | -100.0K | 234.0K | -30% | -$1.02M |
| D | 2022-02-22 | 2022-02-18 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +16.0K | 149.5K | +12% | +$17.0K |
| D | 2022-02-17 | 2022-02-14 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +4,000 | 133.5K | +3% | +$4,240 |
| DM | 2022-02-08 | 2022-02-04 | RXRX | Larson Tina Marriott | Pres, COO | A - Grant | $0.00 | +82.0K | 130.3K | +170% | $0 |
| D | 2022-02-08 | 2022-02-04 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $11.40 | -828 | 129.5K | -0.6% | -$9,439 |
| DM | 2022-02-08 | 2022-02-04 | RXRX | Doyle Ramona | Chief Medical Off | A - Grant | $0.00 | +40.9K | 95.8K | +74% | $0 |
| D | 2022-02-08 | 2022-02-04 | RXRX | Doyle Ramona | Chief Medical Off | F - Tax | $11.40 | -981 | 97.2K | -1.0% | -$11.2K |
| DM | 2022-02-08 | 2022-02-04 | RXRX | Virani Shafique | Chief Corp. Dev. Off | A - Grant | $0.00 | +42.9K | 103.7K | +71% | $0 |
| D | 2022-02-08 | 2022-02-04 | RXRX | Virani Shafique | Chief Corp. Dev. Off | F - Tax | $11.40 | -1,114 | 105.3K | -1% | -$12.7K |
| DM | 2022-02-08 | 2022-02-04 | RXRX | Secora Michael | CFO | A - Grant | $0.00 | +60.3K | 590.4K | +11% | $0 |
| D | 2022-02-08 | 2022-02-04 | RXRX | Secora Michael | CFO | F - Tax | $11.40 | -678 | 589.8K | -0.1% | -$7,729 |
| DM | 2022-02-08 | 2022-02-04 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +210.9K | 234.4K | +899% | $0 |
| D | 2022-02-08 | 2022-02-04 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $11.40 | -343 | 234.0K | -0.1% | -$3,910 |
| D | 2022-02-02 | 2022-01-31 | RXRX | Doyle Ramona | Chief Medical Off | M - OptEx | $2.48 | +15.6K | 57.3K | +37% | +$38.8K |
| D | 2022-02-02 | 2022-01-31 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +19.9K | 43.3K | +85% | $0 |
| D | 2022-02-02 | 2022-01-31 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $11.73 | -19.9K | 23.5K | -46% | -$232.9K |
Purchase Sale Sale after option exercise All abbreviations